Pharma's High Hopes for Diabetes Drugs Revived

If the FDA's decision in September 2005 to ask for additional safety data on the dual PPAR agonist muraglitazar (Pargluva, from Bristol-Myers Squibb and Merck) virtually killed development of all such compounds, the data presented less than a year later at the American Diabetes Association annual meeting has Big Pharma excited again about the potential for new classes of diabetes drugs.

If the FDA’s decision in September 2005 to ask for additional safety data on the dual PPAR agonist muraglitazar (Pargluva, from Bristol-Myers Squibb Co. and Merck & Co. Inc. [See Deal]) virtually killed development of all such compounds, the data presented less than a year later at the American Diabetes Association annual meeting has Big Pharma excited again about the potential for new classes of diabetes drugs.

Attendees at that meeting got perhaps their first clear picture of the competitive landscape emerging around inhibitors of the enzyme...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

More from In Vivo